Claris Lifesciences News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Claris Lifesciences from all sources in a single place.

20 Mar 2018

Company Update

Exit Letter Of Offer

BSE India

Exit Letter of Offer to the remaining public shareholders ('Residual Public Shareholders') of Claris Lifesciences Limited ('Company') for the acquisition of 22,88,697 (Twenty Two Lakh Eighty Eight Thousand Six Hundred and Ninety Seven) fully paid up Equity Shares (representing 4.19% of the paid up share capital of the Company) held by the Residual Public Shareholders of the Company, pursuant to Regulation 21 of the Securities and Exchange Board of...

pdf

CLARIS LIFESCIENCES LTD.

13 Mar 2018

Claris Lifesciences shares to delist from BSE on March 22

Business Standard

Promoter Arjun Handa has bought back shares from existing shareholders and now holds 96 per cent in the soon-to-be delisted entity

Claris Lifesciences to delist from March 22

Business Line | 12 Mar 2018 1 more

CLARIS LIFESCIENCES LTD.

12 Mar 2018

Company Update

Announcement under Regulation 30 (LODR)-Updates

BSE India

Delisting Announcement with respect to voluntary delisting of the equity shares of Claris Lifesciences Limited (the 'Company') from BSE Limited in accordance with the provisions of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 as amended from time to time ('Delisting Regulations')

pdf

CLARIS LIFESCIENCES LTD.

12 Mar 2018

Company Update

Announcement under Regulation 30 (LODR)-Updates

BSE India

Exit Offer Public Announcement to the remaining public shareholders ('Residual Public Shareholders') of Claris Lifesciences Limited (the 'Company') made by Athanas Enterprise Private Limited ('AEPL' or the 'Promoter') and Claris Holdings Private Limited ('CHPL') (collectively referred to as 'Acquirers') for the acquisition of 22,88,697 (Twenty Two Lakh Eighty Eight Thousand Six Hundred and Ninety Seven) fully paid up Equity Shares (representing 4.19%...

pdf

CLARIS LIFESCIENCES LTD.

07 Mar 2018

SAST

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Credit Suisse Finance (India) Pvt Ltd

pdf

CLARIS LIFESCIENCES LTD.

28 Feb 2018

SAST

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Athanas Enterprise Pvt Ltd and Claris Holdings Pvt Ltd

pdf

CLARIS LIFESCIENCES LTD.

28 Feb 2018

SAST

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Athanas Enterprise Pvt Ltd

pdf

CLARIS LIFESCIENCES LTD.

27 Feb 2018

SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Athanas Enterprise Pvt Ltd & Claris Holdings Pvt Ltd

pdf

CLARIS LIFESCIENCES LTD.

22 Feb 2018

Company Update

Announcement under Regulation 30 (LODR)-Updates

BSE India

Post Offer Public Announcement made by Athanas Enterprise Private Limited ('AEPL' or the 'Promoter') and Claris Holdings Private Limited ('CHPL') (collectively referred to as 'Acquirers') with respect to voluntary delisting of the equity shares of Claris Lifesciences Limited (the 'Company') from BSE Limited in accordance with the provision of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 as amended from time to time ('Delisting Regulations')

pdf

CLARIS LIFESCIENCES LTD.

09 Feb 2018, 11:18PM

Claris Lifesciences: Delisting offer begins

Business Line

The delisting offer to the shareholders of Claris Lifesciences will open on Monday at the BSE. The company, which fixed the floor price at 351.60, plans to buy

Is CLARIS LIFESCIENCES LTD. worth buying?

8 Votes:

Buy 87.5%

Sell 12.5%